Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemic
Limited data are available on the prevalence of prescription opioid use among patients with cardiac conditions who were exposed to increased risks of cardiac events including myocardial failure and cardiac arrest. According to the U.S. National Health Interview Survey, we evaluated the prevalence of...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1127636/full |
| _version_ | 1797902547952861184 |
|---|---|
| author | Lvkan Weng Jingxuan Huang Yanan Lou Haoting Shi Yuantong Ma Siyu Gu Ne Qiang Shuxun Wang Lan Wu Mu He Lei Xu Lefei Han |
| author_facet | Lvkan Weng Jingxuan Huang Yanan Lou Haoting Shi Yuantong Ma Siyu Gu Ne Qiang Shuxun Wang Lan Wu Mu He Lei Xu Lefei Han |
| author_sort | Lvkan Weng |
| collection | DOAJ |
| description | Limited data are available on the prevalence of prescription opioid use among patients with cardiac conditions who were exposed to increased risks of cardiac events including myocardial failure and cardiac arrest. According to the U.S. National Health Interview Survey, we evaluated the prevalence of opioid use in patients with cardiac conditions who reported prescription opioid use in the past 12 months and 3 months in 2019 and 2020, respectively, and further estimated the prevalence of opioid use for acute pain or chronic pain. We also analyzed the stratified prevalence by demographical characteristics. Our results showed that there was no statistically significant change in the prevalence of opioid use in the past 12 months (26.5% in 2019 vs. 25.7% in 2020) or the past 3 months (66.6% in 2019 vs. 62.5% in 2020) before and during the COVID-19 pandemic. However, there was a significant decline in the prevalence of opioid use for acute pain, from 64.2% (95% confidence interval [CI] 57.6% to 70.3%) in 2019 to 49.6% (95% CI 40.1% to 59.0%) in 2020 (P = 0.012), particularly in the subgroups of men, non-Hispanic white people, adults with education below high school, those with an income-to-poverty ratio ranging from 1.0 to 1.9, and those covered with health insurance. Our findings suggest that monitoring opioid use in the era of living with COVID-19 is important, which will help inform healthcare providers to develop care strategies to reduce health loss for vulnerable individuals. |
| first_indexed | 2024-04-10T09:19:26Z |
| format | Article |
| id | doaj.art-1e622b201b154ac2a507ebe80dea3438 |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-04-10T09:19:26Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-1e622b201b154ac2a507ebe80dea34382023-02-20T13:10:47ZengFrontiers Media S.A.Frontiers in Public Health2296-25652023-02-011110.3389/fpubh.2023.11276361127636Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemicLvkan Weng0Jingxuan Huang1Yanan Lou2Haoting Shi3Yuantong Ma4Siyu Gu5Ne Qiang6Shuxun Wang7Lan Wu8Mu He9Lei Xu10Lefei Han11Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSchool of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaImmune Therapy Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSchool of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaSchool of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaSchool of Global Health, Chinese Center for Tropical Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSchool of Global Health, Chinese Center for Tropical Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSchool of Global Health, Chinese Center for Tropical Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSchool of Mathematics and Physics, Xi'an Jiaotong-Liverpool University, Suzhou, ChinaSchool of Mathematics and Physics, Xi'an Jiaotong-Liverpool University, Suzhou, ChinaShanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSchool of Global Health, Chinese Center for Tropical Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaLimited data are available on the prevalence of prescription opioid use among patients with cardiac conditions who were exposed to increased risks of cardiac events including myocardial failure and cardiac arrest. According to the U.S. National Health Interview Survey, we evaluated the prevalence of opioid use in patients with cardiac conditions who reported prescription opioid use in the past 12 months and 3 months in 2019 and 2020, respectively, and further estimated the prevalence of opioid use for acute pain or chronic pain. We also analyzed the stratified prevalence by demographical characteristics. Our results showed that there was no statistically significant change in the prevalence of opioid use in the past 12 months (26.5% in 2019 vs. 25.7% in 2020) or the past 3 months (66.6% in 2019 vs. 62.5% in 2020) before and during the COVID-19 pandemic. However, there was a significant decline in the prevalence of opioid use for acute pain, from 64.2% (95% confidence interval [CI] 57.6% to 70.3%) in 2019 to 49.6% (95% CI 40.1% to 59.0%) in 2020 (P = 0.012), particularly in the subgroups of men, non-Hispanic white people, adults with education below high school, those with an income-to-poverty ratio ranging from 1.0 to 1.9, and those covered with health insurance. Our findings suggest that monitoring opioid use in the era of living with COVID-19 is important, which will help inform healthcare providers to develop care strategies to reduce health loss for vulnerable individuals.https://www.frontiersin.org/articles/10.3389/fpubh.2023.1127636/fullCOVID-19 pandemicopioid useprevalencesurvey studycardiac patients |
| spellingShingle | Lvkan Weng Jingxuan Huang Yanan Lou Haoting Shi Yuantong Ma Siyu Gu Ne Qiang Shuxun Wang Lan Wu Mu He Lei Xu Lefei Han Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemic Frontiers in Public Health COVID-19 pandemic opioid use prevalence survey study cardiac patients |
| title | Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemic |
| title_full | Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemic |
| title_fullStr | Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemic |
| title_full_unstemmed | Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemic |
| title_short | Comparison of the prevalence of opioid use among U.S. adults with cardiac conditions before and during the COVID-19 pandemic |
| title_sort | comparison of the prevalence of opioid use among u s adults with cardiac conditions before and during the covid 19 pandemic |
| topic | COVID-19 pandemic opioid use prevalence survey study cardiac patients |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1127636/full |
| work_keys_str_mv | AT lvkanweng comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT jingxuanhuang comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT yananlou comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT haotingshi comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT yuantongma comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT siyugu comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT neqiang comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT shuxunwang comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT lanwu comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT muhe comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT leixu comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic AT lefeihan comparisonoftheprevalenceofopioiduseamongusadultswithcardiacconditionsbeforeandduringthecovid19pandemic |